Furthermore, in the urothelial carcinoma anti-PDL1 therapy cohort, the percentage of CR/PR patients was higher in PLA2G2D-high patients, which is similar to that in melanoma immunotherapy cohort (Figure 9H). Here, PLA2G2D is linked to urothelial carcinoma.